Acute liver failure related to hepatitis B virus

Hepatology Research

Volumn 38, Issue SUPPL. 1, 2008, Pages

  Lee, Han Chu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute liver failure; HepatitisB virus

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; NUCLEOSIDE ANALOG;

ACUTE HEPATITIS; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NEUROLOGIC DISEASE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SURVIVAL;

EID: 58049120212     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00420.x     Document Type: Conference Paper

References (27)

1. Trey C, Davidson CS. The management of fulminant hepatic disease. Prog Liver Dis 1970; 3: 282-98.
2. O'Grady JG, Schalm SW, Williams R. Acute liver failure: Redefining the syndromes. Lancet 1993; 342: 273-5.
3. Ostapowicz G, Fontana RJ, Schiødt FV etal. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
4. Polson J, Lee WM. AASLD position paper: The management of acute liver failure. Hepatology 2005; 41: 1179-97.
5. Escorsell A, Mas A, de la Mata M; Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: Analysis of 267 cases. Liver Transpl 2007; 13: 1389-95.
6. Sato S, Suzuki K, Takikawa Y, Endo R, Omata M; Japanese National Study Group of Fulminant Hepatitis. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: An analysis of 1309 cases in a 15-year national survey. Hepatol Res 2004; 30: 155-61.
7. Heo NY, Lim YS, Kang JM et al. Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea. Korean J Hepatol 2006; 12: 82-92.
8. Wai C-T, Fontana RJ, Polson J et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005; 12: 192-8.
9. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37: 206-12.
10. Yoo BC, Kim JH, Chung Y-H et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
11. Lau GKK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-Positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
12. Kim JW, Lee HS, Woo GH et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001; 33: 403-5.
13. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-34.
14. Wright TL, Mamish D, Combs C et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992; 339: 952-5.
15. Fagan EA, Harrison TJ. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J Hepatol 1994; 21: 587-91.
16. Mason A, Sallie R, Perrillo R et al. Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non-A, non-B fulminant hepatic failure. Hepatology 1996; 24: 1361-5.
17. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: Summary of a workshop. Hepatology 1995; 21: 240-52.
18. Lettau LA, McCarthy JG, Smith MH et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med 1987; 317: 1256-62.
19. Fagan EA, Smith PM, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBe-positive males. Lancet 1986; 2: 538-40.
20. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324: 1705-9.
21. Tanaka S, Yoshiba M, Iino S et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48: 1972-8.
22. Simini B. Italian outbreak of fulminant hepatitis B reported. Lancet 1998; 351: 653.
23. Sugauchi F, Orito E, Ohno T et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 2006; 36: 107-14.
24. Kim HJ, Yoo BC. The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection. Korean J Hepatol 2002; 8: 149-56.
25. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-63.
26. Seremba E, Sanders CM, Jain MK et al. Use of nucleoside analogues in HBV related acute liver failure. Hepatology 2007; 46(Suppl): 276A.
27. Kumar M, Satapathy S, Monga R et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.